The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7629-7633

  Maley, Carlo C ^a   Galipeau, Patricia C ^a   Li, Xiaohong ^a   Sanchez, Carissa A ^a   Paulson, Thomas G ^a   Blount, Patricia L ^a,b   Reid, Brian J ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CPG ISLAND; ESOPHAGUS CARCINOMA; FEMALE; GENE MUTATION; GENETIC STABILITY; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; MOLECULAR CLONING; PLOIDY; PREDICTION; PRIORITY JOURNAL; TETRAPLOIDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BARRETT ESOPHAGUS; COHORT STUDIES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P16; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED;

EID: 5644255657     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1738     Document Type: Article

References (46)

1. Nowell PC. The clonal evolution of tumor cell populations. Science (Wash DC) 1976;194:23-8.
2. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
3. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3:695-701.
4. Sieber OM, Heininmann K, Tomlinson IPM. Genomic instability - the engine of tumorigenesis? Nat Rev Cancer 2003;3:701-8.
5. Moolgavkar SH, Luebeck EG. Multistage carcinogenesis and the incidence of human cancer. Genes Chromosomes Cancer 2003;38:302-6.
6. Maley CC, Reid BJ. Barrett's esophagus as an example of the evolution of cell lineages in cancer. In: Encyclopedia of the human genome. London, UK: Nature Publishing Group; 2003.
7. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-3.
8. Renan MJ. How many mutations are required for tumorigenesis? implications from human cancer data. Mol Carcinog 1993;7:139-46.
9. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9: 138-41.
10. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-9.
11. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003;100:776-81.
12. Nowak MA, Komarova NL, Sengupta A, et al. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci USA 2002;99:16226-31.
13. Maley CC, Forrest S. Exploring the relationship between neutral and selective mutations in cancer. Artif Life 2000;6:325-45.
14. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
15. Neshat K, Sanchez CA, Galipeau PC, et al. Barrett's esophagus: a model of human neoplastic progression. Cold Spring Harb Symp Quant Biol 1994;59:577-83.
16. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
17. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
18. Wong DJ, Paulson TG, Prevo LJ, et al. p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
19. Levine DS, Reid BJ. Endoscopic diagnosis of esophageal neoplasms. Gastrointest Endosc Clin N Am 1992;2:395-413.
20. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
21. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
22. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
23. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25:982-93.
24. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-27.
25. Gulizia JM, Wang H, Antonioli D, et al. Proliferative characteristics of intestinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett's esophagus): a case control study. Hum Pathol 1999;30:412-8.
26. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer (Phila) 1993;72: 1155-8.
27. Avidan B, Sonnenberg A, Schnell T, Chejfec G, Metz A, Sontag S. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002;97:1930-6.
28. Rudolph RE, Vaughan TL, Storer BE, et al. The effect of segment length on the risk of neoplastic progression in patients with Barrett's esophagus. Ann Intern Med 2000;132:612-20.
29. Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 1991;20:791-816.
30. Cameron AJ. Epidemiologic studies and the development of Barrett's esophagus. Endoscopy 1993;25:635-6.
31. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
32. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999; 9:482-91.
33. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105:119-29.
34. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst (Bethesda) 1999;91:2087-95.
35. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59:4784-7.
36. Hartl DL, Clark AG. Principles of population genetics, Sunderland, MA: Sinauer Associates, Inc.; 1997.
37. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 1998;95: 13692-7.
38. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature (Lond) 1998;396:643-9.
39. Matzke MA, Mette MF, Kanno T, Matzke AJM. Does the intrinsic instability of aneuploid genomes have a causal role in cancer? Trends Genet 2003;19:253-6.
40. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 2001;1:109-17.
41. Shackney SE, Smith CA, Miller BW, et al. Model for the genetic evolution of human solid tumors. Cancer Res 1989;49:3344-54.
42. Shao C, Deng L, Henegariu O, Liang L, Stambrook PJ, Tischfield JA. Chromosome instability contributes to loss of heterozygosity in mice lacking p53. Proc Natl Acad Sci USA 2000;97:7405-10.
43. Xia F, Wang X, Wang YH, et al. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995;55:12-5.
44. Honma M, Hayashi M, Sofuni T. Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutated human lymphoblastoid cells. Mutat Res 1997;374:89-98.
45. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomark Prev 2004;13:1375-84.
46. Gatenby RA, Vincent TL. Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther 2003;2:919-27.